Chronic Pain Clinical Trial
Official title:
The Analgesic Efficacy of Δ9-THC (Namisol®) in Patients With Persistent Postsurgical Abdominal Pain; a Randomized, Double Blinded, Placebo-controlled, Experiment
Persistent postsurgical abdominal pain (PPAP) is a very difficult to treat pain. This pain
can persist for months or even years and significantly diminishes quality of life. The exact
underlying cause for this pain persistence is still unclear, which makes its treatment still
a challenge. The promising analgesic effects of Δ9-THC in previous research, plus the
improved bioavailability of Namisol® in comparison with previous Δ9-THC substances form the
basis of the present research proposal.
The current study aims to investigate the analgesic efficacy of Namisol® as add-on analgesic
during a long-term treatment (52 days) of persistent postsurgical abdominal pain.
Status | Completed |
Enrollment | 36 |
Est. completion date | June 2014 |
Est. primary completion date | June 2014 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Aged 18 years or older - Pain should have developed after a surgical procedure - Pain duration exceeding 3 months, and average NRS=3 - Stable doses intake of analgesics for the past 2 months - The patient has been informed about the study, understood the information and signed the informed consent form Exclusion Criteria: - Diagnosed irritated bowel syndrome (IBS) or chronic pancreatitis - Patient took cannabinoids on a regular basis for at least one year - Patient does not feel a pinprick test in the lower extremities - Patient has a body mass index (BMI) above 36,0 kg/m2 - Patient suffers from serious painful conditions other than chronic pancreatitis - Patient has a significant medical disorder that may interfere with the study or may pose a risk for the patient - Patient uses any kind of concomitant medication that may interfere with the study or may pose a risk for the patient - Patient does not tolerate oral intake of medication or liquids, or is refrained from oral intake because of medical reasons - Patient demonstrates clinical relevant deviations in the electrocardiogram (ECG) - Patient has an actual moderate to severe renal impairment - Patient has an actual moderate to severe hepatic impairment - Patient has a presence or history of major psychiatric illness - Patient has experienced an epileptic seizure in the past - Patient demonstrates clinically significant laboratory abnormalities - Patient demonstrates a positive urine drug screen for THC, cocaine, MDMA, and amphetamines - Patient demonstrates a positive test result on hepatitis B surface antigen, hepatitis C antibody or HIV antibody test - Patient has a history of sensitivity / idiosyncrasy to THC - Patient has a known or suspected lactose intolerance - Female patient is pregnant or breastfeeding - Patient intends to conceive a child during the course of the study - Patient participates in another investigational drug study - Patient has a clinical significant exacerbation in illness - Patient is unwilling or unable to comply with the lifestyle guidelines |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Netherlands | Radboud University Nijmegen Medical Centre | Nijmegen |
Lead Sponsor | Collaborator |
---|---|
Radboud University | European Union |
Netherlands,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Average VAS pain | The primary outcome measure is defined as the reduction in average VAS pain scores at the end of the study (day 50-52) compared to the pre-treatment level between the Namisol® and placebo group, measured by a Visual Analoge Scale (VAS) in a pain diary. | Baseline versus day 52 | No |
Secondary | Electroencephalogram (EEG) | Evoked potentials to noxious electrical stimuli, evoked potentials to auditory stimuli (oddball), and spontaneous brain activity will be measured in the electroencephalogram (EEG). | Baseline versus day 52 | No |
Secondary | Quantitative Sensory Testing (QST) | Pressure pain thresholds, electrical thresholds, electric wind-up response, and Diffuse Noxious Inhibitory Control (DNIC) will be measured using Quantitative Sensory Testing (QST). | Baseline versus day 15 and day 52 | No |
Secondary | Depression and (pain related) anxiety | Depression and (pain related) anxiety measured by questionnaires. | Baseline versus day 52 | No |
Secondary | Pharmacodynamic parameters | Pharmacodynamics measured by body sway and questionnaires (VASBond & Lader and VASBowdle) | Baseline versus day 15 and day 52 | No |
Secondary | Safety parameters | Laboratory Electrocardiogram (ECG) Heart Frequency (HF) / Blood Pressure (BP) Adverse Events (AE) |
Baseline until follow-up (day 59-61) | Yes |
Secondary | Quality of life | Quality of life will be evaluated by questionnaires | Baseline versus day 52 | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01659073 -
Using Perfusion MRI to Measure the Dynamic Changes in Neural Activation Associated With Caloric Vestibular Stimulation
|
N/A | |
Recruiting |
NCT05914311 -
Use of Dermabond in Mitigation of Spinal Cord Stimulation (SCS) Trial Lead Migration
|
N/A | |
Recruiting |
NCT05422456 -
The Turkish Version of Functional Disability Inventory
|
||
Enrolling by invitation |
NCT05422443 -
The Turkish Version of Pain Coping Questionnaire
|
||
Completed |
NCT05057988 -
Virtual Empowered Relief for Chronic Pain
|
N/A | |
Completed |
NCT04385030 -
Neurostimulation and Mirror Therapy in Traumatic Brachial Plexus Injury
|
N/A | |
Recruiting |
NCT06206252 -
Can Medical Cannabis Affect Opioid Use?
|
||
Completed |
NCT05103319 -
Simultaneous Application of Ketamine and Lidocaine During an Ambulatory Infusion Therapy as a Treatment Option in Refractory Chronic Pain Conditions
|
||
Completed |
NCT03687762 -
Back on Track to Healthy Living Study
|
N/A | |
Completed |
NCT04171336 -
Animal-assisted Therapy for Children and Adolescents With Chronic Pain
|
N/A | |
Completed |
NCT03179475 -
Targin® for Chronic Pain Management in Patients With Spinal Cord Injury
|
Phase 4 | |
Completed |
NCT03418129 -
Neuromodulatory Treatments for Pain Management in TBI
|
N/A | |
Completed |
NCT03268551 -
MEMO-Medical Marijuana and Opioids Study
|
||
Recruiting |
NCT06204627 -
TDCS* and Laterality Trainnning in Patients With Chronic Neck Pain
|
N/A | |
Recruiting |
NCT06060028 -
The Power of Touch. Non-Invasive C-Tactile Stimulation for Chronic Osteoarthritis Pain
|
N/A | |
Completed |
NCT05496205 -
A SAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT00983385 -
Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Chronic Low Back Pain Taking Either WHO Step I or Step II Analgesics or no Regular Analgesics
|
Phase 3 | |
Recruiting |
NCT05118204 -
Randomized Trial of Buprenorphine Microdose Inductions During Hospitalization
|
Phase 4 | |
Terminated |
NCT03538444 -
Repetitive Transcranial Magnetic Stimulation for Opiate Use Disorder
|
N/A | |
Not yet recruiting |
NCT05812703 -
Biometrics and Self-reported Health Changes in Adults Receiving Behavioral Treatments for Chronic Pain
|